Background Image

Our Team



Chief Executive Officer

Paul Holzer served as a US Navy SEAL Officer for 10 years and attained the rank of Lieutenant Commander. While serving overseas, he witnessed the horrific effects of severe burns and other combat injuries, fostering an interest in improving the availability of effective, life saving medical devices. This interest was developed through his master's training as a Mechanical Engineer at the Massachusetts Institute of Technology and his experience a Paramedic/EMT. He applied these skills as a Research Fellow at the Massachusetts General Hospital (MGH) investigating skin graft and vascularized allograft solutions Transplantation Biology Research Center (TBRC). He is simultaneously completing his PhD curriculum at Dartmouth's Geisel School of Medicine(c) and his MBA, with an emphasis in Economics, at Southern New Hampshire University(c).



Director of Research
Clinical Trial Coordinator

Bo Overschmidt graduated from the University of Missouri with dual degrees in Biological Sciences and Economics prior to pursuing his medical education at the Washington University in St. Louis School of Medicine. While exploring the discipline of plastic surgery in medical school, he discovered a passion for burn care and reconstructive surgery. He brings a broad experience in basic science, translational, and clinical research in biochemistry and surgery to the Xenotherapeutics team, where he will serve as the coordinator for the clinical trial and preclinical research efforts. After completion of the clinical trial he plans to further pursue his training in Plastic and Reconstructive Surgery.



Director of Grants

Laurence graduated from the College of William and Mary with a B.Sc. in Biology in 2014. He has extensive experience in academic, wet-bench research, including multiple publications. Since transitioning into industry, Laurence has enjoyed working with small, rapidly growing companies by establishing a US presence and as a regulatory consultant. He joined XenoTherapeutics to advance burn care through innovative solutions and will continue to use his strong scientific writing skills to further the Xenotherapeutics mission.